Form 4: KalVista Pharmaceuticals CEO Benjamin Palleiko Reports Stock Transactions
SEC Form 4 Filing
CEO Benjamin Palleiko reports the vesting and sale of KalVista Pharmaceuticals stock to cover tax obligations.
Summary
- On February 17, 2025, Benjamin L. Palleiko, CEO of KalVista Pharmaceuticals, exercised restricted stock units (RSUs) and performance stock units (PSUs) converting them into 9,363 shares of common stock.
- On February 18, 2025, Palleiko sold 5,104 shares of common stock at a price of $9.8242 per share.
- These transactions were reported on a Form 4 filing with the SEC.
- The sale was to cover tax withholding obligations related to the vesting of the RSUs and PSUs and was not a discretionary transaction.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing related to stock transactions by the CEO. It doesn't inherently indicate positive or negative sentiment, as it's a standard reporting requirement.
Management Comments
- The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders due to the increased supply of shares, but it is unlikely to be significant given the relatively small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| August 17, 2022 | Vesting Commencement Date for 1/16th of total shares subject to RSU. |
| November 17, 2022 | Vesting Commencement Date for 1/12th of total shares subject to RSU. |
| February 17, 2025 | Date of RSU and PSU exercise. |
| February 18, 2025 | Date of stock sale to cover tax obligations. |
| February 19, 2025 | Date of signature on the Form 4 filing. |
Keywords
KalVista Pharmaceuticals, Benjamin Palleiko, Form 4, SEC, Stock Sale, RSU, PSU, Vesting, Tax Withholding, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.